drugset / Trial / NCT05914935
Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma
Phase 0
Unknown
6 enrolled
Binhai Hospital of Fujian Medical University
Shanghai Yuansong Biotechnology Co., LTD · collab
NaSingle-groupOpen-labelTreatment
Summary
The target subjects were patients with histologically or cytologically confirmed recurrent glioblastoma.Six subjects were expected to be enrolled,the number of subjects will be adjusted according to the course and outcome of the trial.The aim of this study was to evaluate the safety and tolerability of recombinant L-IFN adenovirus injection in the treatment of patients with recurrent glioblastoma, and to determine the registered clinical recommended dose and dosing regimen.
Timeline
- Start
- 2023-06-27
- Primary completion
- 2024-06-12
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant L-IFN adenovirus | Unknown | 5e+10 unknown | Other |